# Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

> **NCT06862284** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Primary Sjögren's Syndrome (pSS)

## Interventions

- **DRUG:** Upadacitinib (ABT-494)
- **DRUG:** Hydroxychloroquine (HCQ)

## Key facts

- **NCT ID:** NCT06862284
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06862284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06862284, "Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06862284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*